randomized, double-blinded, phase 2 trial of wr 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in this randomized, double-blinded phase 2 trial, 30 patients with leishmania panamensis cutaneous leishmaniasis were randomly allocated (1:1) to receive once daily topical treatment with wr 279,396 (15% paromomycin + 0.5% gentamicin) or paromomycin alone (15% paromomycin) for 20 days. the index lesion cure rate after 6 months follow-up was 13 of 15 (87%) for wr 279,396 and 9 of 15 (60%) for paromomycin alone (p = 0.099). when all treated lesions were included, the final cure rate for wr 279,398 ...201323857024
aflp polymorphisms allow high resolution genetic analysis of american tegumentary leishmaniasis agents circulating in panama and other members of the leishmania genus.american tegumentary leishmaniasis is caused by parasites of the genus leishmania, and causes significant health problems throughout the americas. in panama, leishmania parasites are endemic, causing thousands of new cases every year, mostly of the cutaneous form. in the last years, the burden of the disease has increased, coincident with increasing disturbances in its natural sylvatic environments. the study of genetic variation in parasites is important for a better understanding of the biolog ...201324039881
genome-wide discovery and development of polymorphic microsatellites from leishmania panamensis parasites circulating in central panama.the parasite leishmania panamensis is the main cause of leishmaniasis in panama. the disease is largely uncontrolled, with a rising incidence and no appropriate control measures. while microsatellites are considered some of the best genetic markers to study population genetics and molecular epidemiology in these and other parasites, none has been developed for l. panamensis.201526459121
Displaying items 1 - 3 of 3